Cullinan Therapeutics的动态

?? Check out this research investigating factors that could alter the likelihood of identifying a clinically actionable #germline #pathogenic variant in patients with #UC. ?? Learn More:

A cystic fibrosis diagnosis once meant a life expectancy only through early adulthood. However, thanks to the development of therapeutics that target the CFTR proteins responsible for this disease, CF patients can now expect to live significantly longer than before. In a recent article exploring treatment options for #CF, our very own trial manager with extensive experience in this space, Nadia Shive, shared her insights on these vital therapies, challenges in cystic fibrosis clinical trials, and more in Labiotech.eu. Read the full article here: https://lnkd.in/eTnC5VEU #respiratoryhealth #cysticfibrosis #cysticfibrosismarket #clinicaltrials

"The more we did, the more we saw we were actually changing paradigms." The latest op-ed from Jürgen Eckhardt discusses the revolutionary potential of CAR-T #celltherapy in treating #autoimmunediseases as recent studies have shown remarkable results for patients with severe autoimmune conditions like #lupus. One inspiring case involved a young woman with a critical case of lupus who had no other treatment options. After receiving CAR T-cell therapy, she not only survived but thrived, passing the 1000-day mark of remission and reclaiming her life. Such stories underscore the transformative potential of CAR T-cell therapy, which was initially developed for blood cancers but now shows promise for autoimmune diseases. Our portfolio company, Capstan Therapeutics, is pioneering in vivo CAR-T therapies, which aim to simplify and scale this potentially revolutionary treatment. By leveraging #mRNA technology, Capstan's approach could enable the patient's body to produce CAR T cells directly, making the treatment more accessible and efficient. Read more on this exciting journey towards better, more effective treatments for autoimmune diseases and beyond: https://lnkd.in/gbVtSEGM

From the #StemCellEvidence Alert: Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial by Moreau et al. https://lnkd.in/eg8KKXhm

?? #ICYMI: Check out this research investigating factors that could alter the likelihood of identifying a clinically actionable #germline #pathogenic variant in patients with #UC. ?? Learn More:

Today is World Cholangiocarcinoma Day. It's a day to "raise much-needed awareness" of CCA & advocate for a "smoother journey to diagnosis," according to the Global Cholangiocarcinoma Alliance. Don't miss this insightful new article on CCA by our contributor Amanda Brink, DNP, APRN, FNP-BC, AOCNP, who discusses the importance of molecular testing for these patients: https://buff.ly/49gUZKK #WorldCCADay #BeClearOnCCA

Survival outcomes on CDK4/6 inhibitors from two trials - based on intrinsic subtypes https://lnkd.in/dsH5fT2e 2nd generation Genexpression tests can generate clinical insights.

#Celltherapies represent a groundbreaking approach to treating a diverse spectrum of diseases, ranging from rare cancers to degenerative disorders and autoimmune conditions, by leveraging the body's own cells. However, navigating the complex journey to access these therapies can be challenging for patients, involving stringent screening, personalized treatment strategies, and vigilant monitoring for safety and efficacy. Our recent webinar delves into this intricate end-to-end process, featuring insights from two experts at Thermo Fisher Scientific. They explore how partnering with an integrated #CRO/#CDMO can streamline the development-to-manufacturing pathway, easing industry challenges and expediting patient access to life-changing treatments. Watch it here: https://spr.ly/6043b0jkZ

Acalabrutinib, a second-generation, covalent Bruton tyrosine kinase inhibitor, demonstrated progression-free survival benefit and/or favorable tolerability vs comparators in patients with treatment-naive and relapsed/refractory CLL. This study assesses the impact of dose modifications or discontinuations that occur in the first year of acalabrutinib in treatment-naive patients on overall survival (OS), in patients with treatment-naive CLL, and in patients with relapsed/refractory CLL. In this MEDtalk, Alessandra Tedeschi presents the results. ??Follow our coverage of EHA 2024 right here: https://lnkd.in/dPW-ansy #EHA24 #CLL?

Acalabrutinib, a second-generation, covalent Bruton tyrosine kinase inhibitor, demonstrated progression-free survival benefit and/or favorable tolerability vs comparators in patients with treatment-naive and relapsed/refractory CLL. This study assesses the impact of dose modifications or discontinuations that occur in the first year of acalabrutinib in treatment-naive patients on overall survival (OS), in patients with treatment-naive CLL, and in patients with relapsed/refractory CLL. In this MEDtalk, Alessandra Tedeschi presents the results. ??Follow our coverage of EHA 2024 right here:?https://lnkd.in/dGGgc_CW #EHA24 #CLL?